Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
E K RowinskyR C Donehower

Abstract

A phase I and pharmacologic study was performed to evaluate the feasibility of administering the topoisomerase I (topo I) inhibitor topotecan (TPT) in combination with cisplatin (CDDP) in minimally pretreated adults with solid tumors. The study was designed to evaluate the magnitude of the toxicologic and pharmacologic differences between the two sequences of drug administration. TPT was administered as a 30-minute infusion daily for 5 days and CDDP was given either before TPT on day 1 or after TPT on day 5. Each patient was treated with both schedules on an alternating basis every 3 weeks. Sequential dose escalation of TPT or CDDP resulted in three dosage permutation of TPT/CDDP (mg/m2): 0.75/50, 1/50, and 0.75/75. After the maximum-tolerated dose (MTD) level was achieved, the feasibility of using granulocyte colony-stimulating factor (G-CSF) to permit further dose escalation was studied. To examine the interaction of TPT and CDDP in vitro, human A549 lung cancer cells were exposed to these agents concurrently and sequentially. Dose-limiting neutropenia and thrombocytopenia resulted after the doses of TPT or CDDP were increased to greater than 0.75 and 50 mg/m2, respectively, without and with G-CSF. The sequence of CDDP before...Continue Reading

Citations

Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V M HerbenW W ten Bokkel Huinink
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J de JongeJ Verweij
Oct 9, 2004·The Journal of Biological Chemistry·Robert C A M van WaardenburgJan H M Schellens
May 26, 2006·Expert Opinion on Pharmacotherapy·D PectasidesT Economopoulos
Oct 27, 2007·The Oncologist·Mary O'BrienRodryg Ramlau
Jun 15, 2012·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Hajime AbeTohru Tani
Jan 18, 2014·Statistics in Biopharmaceutical Research·Thomas M Braun, Nan Jia
Feb 1, 2015·Pediatric Blood & Cancer·Kavita RadhakrishnanMitchell S Cairo
May 7, 2002·Journal of Pediatric Hematology/oncology·Robert J WellsSusan R Wiersma
Jun 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M GalloS D Baker
Oct 7, 2005·Cancer Chemotherapy and Pharmacology·Keiichi FujiwaraMitsune Tanimoto
Mar 10, 2006·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Jörg T Hartmann, Hans-Peter Lipp
Oct 13, 2010·Japanese Journal of Clinical Oncology·Yukito IchinoseKoshiro Watanabe
Oct 8, 1999·International Journal of Urology : Official Journal of the Japanese Urological Association·S NaitoH Koga
May 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J de JongeJ Verweij
Jul 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A BowmanJ F Smyth
Oct 27, 2004·Expert Opinion on Pharmacotherapy·Tanya Ahmad, Martin Gore
Jan 7, 1999·The Annals of Pharmacotherapy·R J Cersosimo
Sep 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W C ZamboniK H Tkaczuk
Feb 22, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J SchilderR F Ozols
Dec 19, 2002·Journal of the National Cancer Institute·Sharyn D BakerAlex Sparreboom
Oct 12, 2000·Medical and Pediatric Oncology·C Rodriguez-GalindoP J Houghton
Jan 30, 2007·Expert Opinion on Pharmacotherapy·Leslie M Randall-Whitis, Bradley J Monk
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Uma H AthaleRichard L Heideman
Oct 13, 2010·Journal of the National Cancer Institute·William P McGuire
Jun 18, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David S BossJan H M Schellens
Dec 20, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alejandro D RicartEric K Rowinsky
Sep 17, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Scott H KaufmannCharles Erlichman
Sep 21, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M SorensenH H Hansen
Jun 17, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T OguriM Yamakido
Dec 10, 2002·Cancer Treatment Reviews·M CrulJ H M Schellens
Oct 31, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·U SeifartM Wolf

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
A BowmanJ F Smyth
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Alejandro D RicartE K Rowinsky
© 2021 Meta ULC. All rights reserved